No. Retatrutide is an investigational compound, which means it has not been approved by the US Food and Drug Administration or any other regulator. Because it is not approved, it is not a prescription medicine and is not sold as an approved drug product. As supplied by a research vendor, it is a research material for laboratory use only.
For the molecule’s identity and mechanism, see the companion guides on what retatrutide is and how it works. retatrutide research peptides are supplied for laboratory research use only, and this article describes regulatory status, not any direction for use.
Investigational is not the same as approved
An approved prescription drug has passed a regulator’s review of its safety and effectiveness for a defined use, carries regulator-reviewed labeling, and is dispensed under a prescription. Retatrutide has not reached that point with any regulator, so by definition it is not a prescription medicine.
Instead it is handled as a research chemical. That status is a plain description of where the compound sits in the regulatory process, and it is the reason research vendors label it for research and development use only rather than presenting it as a medicine.
What investigational means in practice
Investigational means the compound is still being studied in clinical trials rather than marketed as a finished product. Retatrutide has moved through early-phase studies into a large phase 3 program run by its developer, and those studies are registered publicly, where the status of a given trial can be checked on ClinicalTrials.gov.
Running registrational trials is the normal path a compound follows before any regulatory decision. Reaching phase 3 is a significant milestone, but it is not approval. Approval, if it happens, is a separate step that a regulator takes after reviewing the trial data, and it has not occurred for retatrutide.
How it differs from an approved medicine
Some compounds in the broader GLP-1 area are approved and available by prescription, with brand names and defined, regulator-reviewed uses. Retatrutide does not share that status, so comparing it directly to an approved product can mislead if the difference is not stated plainly.
The practical result is that a pharmacy does not dispense retatrutide as an approved drug. It moves through the research-supply channel instead, with documentation by product and lot, and its regulatory position is different from that of any approved compound in the same broad class.
What the status means for research use
Because retatrutide is investigational, a research vendor supplies it strictly for laboratory work, and the regulatory status is stated as a fact rather than a judgment about the underlying science, which continues to be studied in trials. The label reflects the process, not an opinion about the molecule.
Anyone sourcing the material should read the product record and the Certificate of Analysis for the specific lot and confirm that the intended work is a legitimate research use consistent with the research-only supply and with any institutional and legal requirements that apply.
Research use only
This article explains the regulatory status of retatrutide research peptides. It is a scientific reference and is not a statement of regulatory approval, medical availability, or any instruction for use.
All products are supplied for research and development use only. They are not for human or veterinary use, and they are not intended to diagnose, treat, cure, or prevent any disease. Anyone using this material is responsible for handling it in line with institutional requirements and applicable law.